Shin-Etsu Chemical Has Developed an Epoch-making Type of Molding Silicone Rubber That Does Not Require Post Cure
28.9.2020 09:00:00 EEST | Business Wire | Press release
In addition to its already being marketed liquid silicone rubber form, Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President, Yasuhiko Saitoh) has now developed a molding silicone rubber that also does not require post cure in its millable form.
Shin-Etsu is the first in the industry to have developed a millable (high consistency) type* of silicone rubber that does not require a post cure. Shin-Etsu succeeded in developing this breakthrough product by making use of the unique technology that Shin-Etsu Chemical has cultivated over a long period of years.
In the existing molding method for millable-type silicone rubber, after the initial press cure of the silicone molding is performed, a post cure is carried out in order to drive off the residues that are left within the molded product as a result of the vulcanization agent used in rubber molding as well as the low-molecular siloxane.
Compared to the existing product, the new silicone rubber molding product that Shin-Etsu has developed greatly reduces the amount of low-molecular siloxane content, and by employing an addition-reaction cure system that does not create by-products at the time of a press cure, the process of post cure becomes unnecessary. Because of this, our new product will contribute to molding-makers’ productivity improvements and energy saving, and at the same time, we are expecting that this new product will respond to such customer requests as preventing the adhesion of foreign substances to the molded products.
Furthermore, this new product is suitable for various molding methods such as extrusion molding, transfer molding, calender molding, press molding and injection molding.
With regard to its liquid-type silicone rubber, already ahead of others in the industry, Shin-Etsu Chemical is marketing its LIMS (Liquid Injection Molding System) materials that do not require post cure, and LIMS is being widely used in various fields, mainly for applications in automobile parts.
In September 2017 Shin-Etsu Chemical opened a silicone rubber molding technical center. This Shin-Etsu Molding Technical Laboratory is located in Higashimatsuyama City, Saitama Prefecture, Japan. At this Laboratory a millable injection-molding machine is installed, and we will be carrying out demonstrations there of molding using this new product. Going forward, at this Laboratory we will strive to meet the current and also future requests that are received from our customers by enhancing the technical services we will be able to offer to them.
Silicone rubber combines many superior characteristics such as excellent heat resistance, cold resistance, weatherability and stable electrical insulation properties, all of which are not found in ordinary organic rubber. For this reason, it is used in a wide range of applications such as in automobiles, electric-electronics equipment, OA equipment, home appliances and products for daily use.
Taking advantage of Shin-Etsu Chemical's superior product quality and technological strengths as well as our system for detailed response to our customers' requests, going forward Shin-Etsu will continue to strive to meet the needs of the diversifying market.
* millable type: It involves the use of a mixer, called a “roll mill,” and it is a general term for rubber materials that are being mixed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200927005079/en/
Contact information
For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-3246-5091, or from outside Japan: 81-3-3246-5091
Fax: 03-3246-5096, or from outside Japan: 81-3-3246-5096
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 16:30:00 EET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom